CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 119 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $46,000 | +39.4% | 15,600 | +47.2% | 0.01% | +50.0% |
Q1 2022 | $33,000 | -8.3% | 10,600 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $36,000 | -18.2% | 10,600 | -12.4% | 0.00% | +300.0% |
Q3 2021 | $44,000 | -17.0% | 12,100 | 0.0% | 0.00% | -83.3% |
Q2 2021 | $53,000 | -10.2% | 12,100 | -6.9% | 0.01% | -25.0% |
Q1 2021 | $59,000 | – | 13,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |